Paper9520131
High plasma levels of apo(a) fragments in Caucasians and African-Americans with end-stage renal disease: implications for plasma Lp(a) assay.
Mooser V and 3 others. Clin Genet, 1997. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. High plasma levels of apo(a) fragments in Caucasians and African-Americans with end-stage renal disease: implications for plasma Lp(a) assay. Papers, record 9520131. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9520131
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Apolipoproteins A | Major topic |
| Kidney Failure, Chronic | Major topic |
| Lipoprotein(a) | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Black People | |
| Female | |
| Heparin | |
| Humans | |
| Kringles | |
| Male | |
| Middle Aged | |
| Peptide Fragments | |
| Regression Analysis | |
| Renal Dialysis | |
| White People | |
| Black or African American |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| HL-30086 | NHLBI NIH HHS | United States | P01HL030086 | PubMed and NIH | NIH RePORTER |
| HL-47619 | NHLBI NIH HHS | United States | R01HL047619 | PubMed and NIH | NIH RePORTER |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42266446 | Lipoprotein(a) in Residual Cardiovascular Risk: Measurement Challenges, Assay Standardisation, and Clinical Implications. | Int J Gen Med | 2026 | https://conductscience.org/library/papers/42266446 | PubMed |
| 36568987 | Higher serum apolipoprotein B level will reduce the bone mineral density and increase the risk of osteopenia or osteoporosis in adults. | Front Cell Dev Biol | 2022 | https://conductscience.org/library/papers/36568987 | PubMed |
| 34033878 | Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation. | Pharmacol Res | 2021 | https://conductscience.org/library/papers/34033878 | PubMed |
| 31551368 | Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis. | J Lipid Res | 2019 | https://conductscience.org/library/papers/31551368 | PubMed |
| 25713100 | IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. | J Lipid Res | 2015 | https://conductscience.org/library/papers/25713100 | PubMed |
| 23484137 | Lipoprotein(a) in cardiovascular diseases. | Biomed Res Int | 2013 | https://conductscience.org/library/papers/23484137 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| APOB | 338 | PubTator's text mining | https://conductscience.org/library/genes/338 | NCBI Gene |
| LPA | 4018 | PubTator's text mining | https://conductscience.org/library/genes/4018 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9520131
GET https://conductscience.org/api/papers/v1/9520131/authors